Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2021 09:05 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitorsTopline data anticipated second half 2023Vitiligo affects...
March 18, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate

STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.Amyloid Light...
March 18, 2021 08:30 ET | Source: Dyadic International, Inc.

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from...
March 18, 2021 08:30 ET | Source: Yield10 Bioscience, Inc.

Yield10 Bioscience to Present at the Benzinga Biotech Small Cap Conference on March 25, 2021

WOBURN, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced that it will be featured as a presenting company at the...
March 18, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st

DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
March 18, 2021 08:00 ET | Source: Talis Biomedical Corporation

Talis Appoints Jeryl Hilleman to Board of Directors

MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at...
March 18, 2021 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020

‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables...
March 18, 2021 08:00 ET | Source: ADMA Biologics, Inc.

ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

RAMSEY, N.J. and BOCA RATON, Fla., March 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,...
March 18, 2021 08:00 ET | Source: Celularity, Inc.

Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of...
March 18, 2021 08:00 ET | Source: Eyenovia, Inc.

Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25

NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose...